Literature DB >> 31669239

Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations.

Indrė Januškevičienė1, Vilma Petrikaitė2.   

Abstract

INTRODUCTION: Breast cancer is the most common cancer and the second leading cause of cancer-related death in women worldwide. Despite the early detection of breast cancer and increasing knowledge of its biology and chemo-resistance, metastatic breast cancer is largely incurable disease. We provide a review of the intertumor and intratumor heterogeneity, explain the differences between triple-negative breast cancer subtypes. Also, we describe the interaction of breast tumor cells with their microenvironment cells and explain how this interaction contributes to the tumor progression, metastasis formation and resistance to the treatment. DISCUSSION: One of the main causes that complicate the treatment is tumor heterogeneity. It is observed among patients (intertumor heterogeneity) and in each individual tumor (intratumor heterogeneity). In the case of intratumor heterogeneity, the tumor consists of different phenotypical cell populations. During breast cancer subtype identification, a small piece of solid tumor tissue does not necessarily represent all the tumor composition. Breast tumor cell phenotypical differences may appear due to cell localization in different tumor sites, unique response to the treatment, cell interaction with tumor microenvironment or tumor cell interaction with each other. This heterogeneity may lead to breast cancer aggressiveness and challenging treatment.
CONCLUSION: Understanding the molecular and cellular mechanisms of tumor heterogeneity that are relevant to the development of treatment resistance is a major area of research. Identification of differences between populations and their response to anticancer drugs would help to predict the potential resistance to chemotherapy and thus would help to select the most suitable anticancer treatment.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell population; Interaction; Intratumor heterogeneity; Phenotypic heterogeneity; Triple-negative breast cancer

Mesh:

Substances:

Year:  2019        PMID: 31669239     DOI: 10.1016/j.lfs.2019.117009

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  40 in total

1.  The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.

Authors:  Maryam Althobiti; Abir A Muftah; Mohammed A Aleskandarany; Chitra Joseph; Michael S Toss; Andrew Green; Emad Rakha
Journal:  Breast Cancer Res Treat       Date:  2020-06-10       Impact factor: 4.872

2.  3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles.

Authors:  Simonas Daunys; Agnė Janonienė; Indrė Januškevičienė; Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Clinical experience of tensor-valued diffusion encoding for microstructure imaging by diffusional variance decomposition in patients with breast cancer.

Authors:  Eun Cho; Hye Jin Baek; Filip Szczepankiewicz; Hyo Jung An; Eun Jung Jung; Ho-Joon Lee; Joonsung Lee; Sung-Min Gho
Journal:  Quant Imaging Med Surg       Date:  2022-03

4.  Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.

Authors:  Mingji Jin; Yan Hou; Xiuquan Quan; Liqing Chen; Zhonggao Gao; Wei Huang
Journal:  Int J Nanomedicine       Date:  2021-08-13

5.  The efficacy of continuing nursing interventions on intraoperative pressure ulcer-related complications in breast cancer patients: systematic review and meta-analysis.

Authors:  Lin Ding; Shuang Ding; Chunmei He; Qifa Zhang; Jingjing An
Journal:  Gland Surg       Date:  2022-06

Review 6.  Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours.

Authors:  Ravi Velaga; Sunao Tanaka; Masakazu Toi
Journal:  Cancer Drug Resist       Date:  2022-06-01

7.  Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.

Authors:  Liyun Luo; Zhijie Zhang; Ni Qiu; Li Ling; Xiaoting Jia; Ying Song; Hongsheng Li; Jiansheng Li; Hui Lyu; Hao Liu; Zhimin He; Bolin Liu; Guopei Zheng
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

8.  MAT2A Localization and Its Independently Prognostic Relevance in Breast Cancer Patients.

Authors:  Pei-Yi Chu; Hsing-Ju Wu; Shin-Mae Wang; Po-Ming Chen; Feng-Yao Tang; En-Pei Isabel Chiang
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 9.  The Roles of circMTO1 in Cancer.

Authors:  Wei Liu; Yuanyuan Xiong; Renhua Wan; Renfeng Shan; Jianfeng Li; Wu Wen
Journal:  Front Cell Dev Biol       Date:  2021-06-30

Review 10.  Resolving Metabolic Heterogeneity in Experimental Models of the Tumor Microenvironment from a Stable Isotope Resolved Metabolomics Perspective.

Authors:  Teresa W-M Fan; Richard M Higashi; Yelena Chernayavskaya; Andrew N Lane
Journal:  Metabolites       Date:  2020-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.